Companies in #Chronic Hepatitis B (CHB)
Found 1 company operating in this sector.
Barinthus Biotherapeutics is a UK-headquartered clinical-stage biopharmaceutical company developing immunotherapies designed to reprogram the immune system to treat chronic infectious diseases, autoimmune conditions, and cancer. The company's lead clinical assets include VTP-300 (an immunotherapeutic for chronic hepatitis B being developed in a collaboration and license agreement with the University of Oxford and in combination studies with Arbutus Biopharma), VTP-1100 (a neoantigen cancer immunotherapeutic partnered with Cancer Research UK), and SNTI acquired imetelstat-adjacent telomere programs. The company operates as a UK-incorporated ADR listed on Nasdaq.